Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2021 Nov 1

PMID 34722588

Citations 28

Authors

Alessia Amato

Alessandro Arrigo

Emanuela Aragona

Maria Pia Manitto

Andrea Saladino

Francesco Bandello

Maurizio Battaglia Parodi

Affiliations

Soon will be listed here.

Abstract

Gene therapy cannot be yet considered a far perspective, but a tangible therapeutic option in the field of retinal diseases. Although still confined in experimental settings, the preliminary results are promising and provide an overall scenario suggesting that we are not so far from the application of gene therapy in clinical settings. The main aim of this review is to provide a complete and updated overview of the current state of the art and of the future perspectives of gene therapy applied on retinal diseases. We carefully revised the entire literature to report all the relevant findings related to the experimental procedures and the future scenarios of gene therapy applied in retinal diseases. A clinical background and a detailed description of the genetic features of each retinal disease included are also reported. The current literature strongly support the hope of gene therapy options developed for retinal diseases. Although being considered in advanced stages of investigation for some retinal diseases, such as choroideremia (CHM), retinitis pigmentosa (RP), and Leber's congenital amaurosis (LCA), gene therapy is still quite far from a tangible application in clinical practice for other retinal diseases. Gene therapy is an extremely promising therapeutic tool for retinal diseases. The experimental data reported in this review offer a strong hope that gene therapy will be effectively available in clinical practice in the next years.

Citing Articles

Retinal Inflammation and Reactive Müller Cells: Neurotrophins' Release and Neuroprotective Strategies.

Balzamino B, Cacciamani A, Dinice L, Cecere M, Pesci F, Ripandelli G Biology (Basel). 2025; 13(12.

PMID: 39765697 PMC: 11673524. DOI: 10.3390/biology13121030.

dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa.

Wang Q, Xu X, Chen S, Lu R, Li L, Lo C Sci Adv. 2024; 10(51):eadn7540.

PMID: 39693439 PMC: 11654696. DOI: 10.1126/sciadv.adn7540.

Bridging the gap of vision restoration.

Carleton M, Oesch N Front Cell Neurosci. 2024; 18:1502473.

PMID: 39640234 PMC: 11617155. DOI: 10.3389/fncel.2024.1502473.

Advances and Challenges in Gene Therapy for Inherited Retinal Dystrophies: A Comprehensive Review.

Jain R, Daigavane S Cureus. 2024; 16(9):e69895.

PMID: 39439625 PMC: 11494405. DOI: 10.7759/cureus.69895.

Advances in retina genetics: Progress, potential, and challenges.

Bansal M Indian J Ophthalmol. 2024; 73(Suppl 1):S31-S36.

PMID: 39257094 PMC: 11834934. DOI: 10.4103/IJO.IJO_3334_23.

References

OReilly M, Palfi A, Chadderton N, Millington-Ward S, Ader M, Cronin T . RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet. 2007; 81(1):127-35. PMC: 1950918. DOI: 10.1086/519025. View

Mandelcorn E, Kitchens J, Fijalkowski N, Moshfeghi D . Active aspiration of suprachoroidal hemorrhage using a guarded needle. Ophthalmic Surg Lasers Imaging Retina. 2014; 45(2):150-2. DOI: 10.3928/23258160-20140306-09. View

Berger W, Kloeckener-Gruissem B, Neidhardt J . The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res. 2010; 29(5):335-75. DOI: 10.1016/j.preteyeres.2010.03.004. View

Hauswirth W, Lewin A . Ribozyme uses in retinal gene therapy. Prog Retin Eye Res. 2000; 19(6):689-710. DOI: 10.1016/s1350-9462(00)00007-0. View

Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G . Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019; 25(2):229-233. DOI: 10.1038/s41591-018-0327-9. View

Carvalho L, Xu J, Pearson R, Smith A, Bainbridge J, Morris L . Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet. 2011; 20(16):3161-75. PMC: 3140821. DOI: 10.1093/hmg/ddr218. View

Sundaram V, Wilde C, Aboshiha J, Cowing J, Han C, Langlo C . Retinal structure and function in achromatopsia: implications for gene therapy. Ophthalmology. 2013; 121(1):234-245. PMC: 3895408. DOI: 10.1016/j.ophtha.2013.08.017. View

Marangoni D, Bush R, Zeng Y, Wei L, Ziccardi L, Vijayasarathy C . Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice. Mol Ther Methods Clin Dev. 2016; 5:16011. PMC: 5008245. DOI: 10.1038/mtm.2016.11. View

Aligianis I, Forshew T, Johnson S, Michaelides M, Johnson C, Trembath R . Mapping of a novel locus for achromatopsia (ACHM4) to 1p and identification of a germline mutation in the alpha subunit of cone transducin (GNAT2). J Med Genet. 2002; 39(9):656-60. PMC: 1735242. DOI: 10.1136/jmg.39.9.656. View

10.

Zhang X, Ge X, Shi W, Huang P, Min Q, Li M . Molecular diagnosis of putative Stargardt disease by capture next generation sequencing. PLoS One. 2014; 9(4):e95528. PMC: 3999032. DOI: 10.1371/journal.pone.0095528. View

11.

Gaglione M, Messere A . Recent progress in chemically modified siRNAs. Mini Rev Med Chem. 2010; 10(7):578-95. DOI: 10.2174/138955710791384036. View

12.

Garanto A, Duijkers L, Tomkiewicz T, Collin R . Antisense Oligonucleotide Screening to Optimize the Rescue of the Splicing Defect Caused by the Recurrent Deep-Intronic Variant c.4539+2001G>A in Stargardt Disease. Genes (Basel). 2019; 10(6). PMC: 6628380. DOI: 10.3390/genes10060452. View

13.

Sweeney M, McGee T, Berson E, Dryja T . Low prevalence of lecithin retinol acyltransferase mutations in patients with Leber congenital amaurosis and autosomal recessive retinitis pigmentosa. Mol Vis. 2007; 13:588-93. PMC: 2669503. View

14.

Lam B, Davis J, Gregori N, MacLaren R, Girach A, Verriotto J . Choroideremia Gene Therapy Phase 2 Clinical Trial: 24-Month Results. Am J Ophthalmol. 2018; 197:65-73. DOI: 10.1016/j.ajo.2018.09.012. View

15.

Dulla K, Slijkerman R, van Diepen H, Albert S, Dona M, Beumer W . Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Mol Ther. 2021; 29(8):2441-2455. PMC: 8353187. DOI: 10.1016/j.ymthe.2021.04.024. View

16.

Rivolta C, Berson E, Dryja T . Paternal uniparental heterodisomy with partial isodisomy of chromosome 1 in a patient with retinitis pigmentosa without hearing loss and a missense mutation in the Usher syndrome type II gene USH2A. Arch Ophthalmol. 2002; 120(11):1566-71. DOI: 10.1001/archopht.120.11.1566. View

17.

Xu M, Yang L, Wang F, Li H, Wang X, Wang W . Mutations in human IFT140 cause non-syndromic retinal degeneration. Hum Genet. 2015; 134(10):1069-78. PMC: 4565766. DOI: 10.1007/s00439-015-1586-x. View

18.

Vasconcelos Jr H, Lujan B, Pennesi M, Yang P, Lauer A . Intraoperative optical coherence tomographic findings in patients undergoing subretinal gene therapy surgery. Int J Retina Vitreous. 2020; 6:13. PMC: 7193395. DOI: 10.1186/s40942-020-00216-1. View

19.

Gal A, Orth U, Baehr W, Schwinger E, Rosenberg T . Heterozygous missense mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal dominant stationary night blindness. Nat Genet. 1994; 7(4):551. DOI: 10.1038/ng0894-551a. View

20.

Remmer M, Rastogi N, Ranka M, Ceisler E . Achromatopsia: a review. Curr Opin Ophthalmol. 2015; 26(5):333-40. DOI: 10.1097/ICU.0000000000000189. View